Gender-Specific Metabolomics Approach to Kidney Cancer

Renal cell carcinoma (RCC) is the most common form of kidney malignancy. RCC is more common among men with a 2/1 male/female incidence ratio worldwide. Given the underlying epidemiological differences in the RCC incidence between males and females, we explored the gender specific 1H NMR serum metabolic profiles of RCC patients and their matched controls. A number of differential metabolites were shared by male and female RCC patients. These RCC specific changes included lower lactate, threonine, histidine, and choline levels together with increased levels of pyruvate, N-acetylated glycoproteins, beta-hydroxybutyrate, acetoacetate, and lysine. Additionally, serum lactate/pyruvate ratio was a strong predictor of RCC status regardless of gender. Although only moderate changes in metabolic profiles were observed between control males and females there were substantial gender related differences among RCC patients. Gender specific metabolic features associated with RCC status were identified suggesting that different metabolic panels could be leveraged for a more precise diagnostic.

Download Full-text

Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

PLoS ONE ◽

10.1371/journal.pone.0166482 ◽

2016 ◽

Vol 11 (11) ◽

pp. e0166482 ◽

Cited By ~ 12

Author(s):

Jie Shen ◽

Zhen Chen ◽

Qianfeng Zhuang ◽

Min Fan ◽

Tao Ding ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Lactate Dehydrogenase ◽

Cell Carcinoma ◽

Renal Cell ◽

Prognostic Value ◽

Meta Analysis ◽

Serum Lactate ◽

Serum Lactate Dehydrogenase

Download Full-text

Loss of nuclear p27kip1 and α-dystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma

Cancer Science ◽

10.1111/j.1349-7006.2010.01644.x ◽

2010 ◽

Vol 101 (9) ◽

pp. 2080-2086 ◽

Cited By ~ 13

Author(s):

Alessandro Sgambato ◽

Andrea Camerini ◽

Giannicola Genovese ◽

Filomena De Luca ◽

Paolo Viacava ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Strong Predictor ◽

Poor Outcome ◽

Frequent Event

Download Full-text

387: The Immunomodulatory Protein B7-H4 Expression in Renal Cell Carcinoma Patients: A Strong Predictor of Cancer Progression and Survival

The Journal of Urology ◽

10.1016/s0022-5347(18)32643-0 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 127-127

Author(s):

Amy E. Krambeck ◽

Eugene Parks ◽

Christine M. Lohse ◽

John C. Cheville ◽

Haidong Dong ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Cancer Progression ◽

Renal Cell ◽

Strong Predictor ◽

Immunomodulatory Protein

Download Full-text

Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4631 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4631-4631 ◽

Cited By ~ 9

Author(s):

A. J. Armstrong ◽

D. J. George ◽

S. Halabi

Keyword(s):

Renal Cell Carcinoma ◽

Lactate Dehydrogenase ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Serum Lactate ◽

Serum Lactate Dehydrogenase ◽

Mtor Inhibition

Download Full-text

Is RCC truly radioresistant? Local control rates of metastatic renal cell carcinoma (RCC) to the lung using stereotactic radiotherapy (SBRT).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.7_suppl.445 ◽

2015 ◽

Vol 33 (7_suppl) ◽

pp. 445-445 ◽

Cited By ~ 2

Author(s):

Basel M Altoos ◽

Arya Amini ◽

Maria Teresa Bourlon ◽

Christine M. Fisher ◽

Edward Bedrick ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Local Control ◽

Renal Cell ◽

Tumor Volume ◽

Strong Predictor ◽

Symptomatic Relief ◽

Univariate Analysis ◽

Local Control Rate ◽

Conventional Fractionation

445 Background: The use of radiation therapy (RT) for renal cell carcinoma (RCC) is controversial because RCC has traditionally been considered to be “radioresistant”. Based on this concern, current studies have suggested the need for higher doses with conventional fractionation (CF) or the use of SBRT with RCC. The purpose of this study is to determine the efficacy of these modalities by comparing the radiographic and symptomatic local control (LC) rates in patients with metastatic RCC to the lung. Methods: We retrospectively analyzed the radiographic and symptomatic RT response in 27 consecutive RCC patients with 37 RCC lung lesions treated between 2005 to 2014. Twenty-six (70.2%) were treated with SBRT and eleven (29.8%) with CF. Only 9 patients (33.3%) had symptoms prior to RT. Median SBRT dose and fraction was 50 Gy (range 25-60) and 3 (range 1-6) versus CF 30 Gy (range 20-55) and 10 (range 5-22) respectively. Toxicity was evaluated by CTCAE 4.0. Results: Median follow up was 16 months (range 1-102). Rates of radiographic local control with SBRT and CF were 92.3% vs. 55.4% respectively (p=0.0016). Under univariate analysis, predictors for radiographic LR were gross tumor volume (GTV) > 20 cc (p < 0.0001), planned tumor volume (PTV) of > 100 cc (p < 0.0001), and biologic effective dose (BED) < 70 Gy (p=0.0001). Subanalysis of CF demonstrated that a BED < 54 Gy was also a strong predictor for LR (p=0.0012). Under multivariate analysis, PTV was a strong predictor for radiographic LR (odds ratio [OR] = 42.2, p=0.0492). For the 9 symptomatic patients, 3 of 4 (75%) patients in the CF arm and 4 of 5 (80%) in the SBRT arm experienced partial or complete symptomatic relief. The median time to relief of symptoms in the SBRT and CF arms were 0.5 and 2 months, respectively. All patients receiving CF had symptomatic LR compared to none in the SBRT arm (p=0.0124). One patient in the SBRT arm had grade 2 hiccups and one with grade 2 pneumonitis in the CF arm. There were no other grade 2 toxicities or higher. Conclusions: SBRT demonstrated an encouraging local control rate and was capable of safely providing symptomatic relief to patients. The traditional view of radioresistance in RCC may not apply in the era of SBRT.

Download Full-text